President Donald Trump's crusade against high drug prices will face some tests in 2019. (Photo: Shutterstock)
For the biopharma industry, 2018 was a year marked by generally robust profits and a handful of superlatives. These include Takeda Pharmaceutical Co.'s $62 billion bid for Shire Plc — the biggest announced drug deal in more than a decade — as well as a record number of approvals of new and generic medicines by the U.S. Food and Drug Administration and the most aggressive drug-pricing proposal to ever emerge from a Republican administration. 
No promises on another megadeal in 2019, but I can guarantee that drug pricing will still be a thing. Here are a few areas I'll be keeping an eye on:
Recommended For You
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
